WO2001064879A2 - G-proteins coupled receptor related polypeptides - Google Patents
G-proteins coupled receptor related polypeptides Download PDFInfo
- Publication number
- WO2001064879A2 WO2001064879A2 PCT/US2001/006474 US0106474W WO0164879A2 WO 2001064879 A2 WO2001064879 A2 WO 2001064879A2 US 0106474 W US0106474 W US 0106474W WO 0164879 A2 WO0164879 A2 WO 0164879A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- amino acid
- nucleic acid
- acid sequence
- group
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 53
- 229920001184 polypeptide Polymers 0.000 title claims abstract 52
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 52
- 108091006027 G proteins Proteins 0.000 title 1
- 102000030782 GTP binding Human genes 0.000 title 1
- 108091000058 GTP-Binding Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 44
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 42
- 108020004707 nucleic acids Proteins 0.000 claims abstract 32
- 102000039446 nucleic acids Human genes 0.000 claims abstract 32
- 230000002265 prevention Effects 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims abstract 3
- 108091033319 polynucleotide Proteins 0.000 claims abstract 3
- 102000040430 polynucleotide Human genes 0.000 claims abstract 3
- 239000002157 polynucleotide Substances 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 15
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000012547 Olfactory receptors Human genes 0.000 claims 3
- 108050002069 Olfactory receptors Proteins 0.000 claims 3
- 230000004075 alteration Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000037353 metabolic pathway Effects 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 210000004379 membrane Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000001706 olfactory mucosa Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
Abstract
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01913168A EP1263952A2 (en) | 2000-02-28 | 2001-02-28 | G-protein coupled receptor related polypeptides |
CA002401453A CA2401453A1 (en) | 2000-02-28 | 2001-02-28 | G-proteins coupled receptor related polypeptides |
JP2001564362A JP2004500098A (en) | 2000-02-28 | 2001-02-28 | G protein-coupled receptor-related polypeptide |
AU2001241859A AU2001241859A1 (en) | 2000-02-28 | 2001-02-28 | Novel proteins and nucleic acids encoding same |
Applications Claiming Priority (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18567400P | 2000-02-28 | 2000-02-28 | |
US18553500P | 2000-02-28 | 2000-02-28 | |
US60/185,535 | 2000-02-28 | ||
US60/185,674 | 2000-02-28 | ||
US18660400P | 2000-03-03 | 2000-03-03 | |
US18682700P | 2000-03-03 | 2000-03-03 | |
US18671900P | 2000-03-03 | 2000-03-03 | |
US18658500P | 2000-03-03 | 2000-03-03 | |
US18671700P | 2000-03-03 | 2000-03-03 | |
US18660600P | 2000-03-03 | 2000-03-03 | |
US18671500P | 2000-03-03 | 2000-03-03 | |
US18671600P | 2000-03-03 | 2000-03-03 | |
US60/186,827 | 2000-03-03 | ||
US60/186,715 | 2000-03-03 | ||
US60/186,585 | 2000-03-03 | ||
US60/186,606 | 2000-03-03 | ||
US60/186,719 | 2000-03-03 | ||
US60/186,717 | 2000-03-03 | ||
US60/186,716 | 2000-03-03 | ||
US60/186,604 | 2000-03-03 | ||
US21832300P | 2000-07-14 | 2000-07-14 | |
US21843500P | 2000-07-14 | 2000-07-14 | |
US60/218,435 | 2000-07-14 | ||
US60/218,323 | 2000-07-14 | ||
US22051700P | 2000-07-24 | 2000-07-24 | |
US60/220,517 | 2000-07-24 | ||
US22389700P | 2000-08-09 | 2000-08-09 | |
US60/223,897 | 2000-08-09 | ||
US26002001P | 2001-01-05 | 2001-01-05 | |
US60/260,020 | 2001-01-05 | ||
US26484901P | 2001-01-26 | 2001-01-26 | |
US60/264,849 | 2001-01-26 | ||
US09/795,271 | 2001-02-27 | ||
US09/795,271 US20030165829A1 (en) | 2000-02-28 | 2001-02-27 | Novel proteins and nucleic acids encoding same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001064879A2 true WO2001064879A2 (en) | 2001-09-07 |
WO2001064879A3 WO2001064879A3 (en) | 2002-05-10 |
Family
ID=27586032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/006474 WO2001064879A2 (en) | 2000-02-28 | 2001-02-28 | G-proteins coupled receptor related polypeptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1263952A2 (en) |
JP (1) | JP2004500098A (en) |
AU (1) | AU2001241859A1 (en) |
CA (1) | CA2401453A1 (en) |
WO (1) | WO2001064879A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077155A2 (en) * | 2000-04-06 | 2001-10-18 | Curagen Corporation | Orfx polynucleotides and polypeptides |
WO2002050117A2 (en) * | 2000-12-18 | 2002-06-27 | Curagen Corporation | G-proteins coupled receptor proteins and nucleic acids encoding same |
JP2003528599A (en) * | 2000-03-14 | 2003-09-30 | トゥラリック インコーポレイテッド | G protein-coupled receptor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0867508A2 (en) * | 1997-03-28 | 1998-09-30 | Smithkline Beecham Corporation | Olfactory receptor of the 7-transmembrane receptor family - OLRCC15 receptor |
WO2001027158A2 (en) * | 1999-10-08 | 2001-04-19 | Digiscents | Olfactory receptor sequences |
-
2001
- 2001-02-28 EP EP01913168A patent/EP1263952A2/en not_active Withdrawn
- 2001-02-28 CA CA002401453A patent/CA2401453A1/en not_active Abandoned
- 2001-02-28 JP JP2001564362A patent/JP2004500098A/en active Pending
- 2001-02-28 AU AU2001241859A patent/AU2001241859A1/en not_active Abandoned
- 2001-02-28 WO PCT/US2001/006474 patent/WO2001064879A2/en active Search and Examination
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0867508A2 (en) * | 1997-03-28 | 1998-09-30 | Smithkline Beecham Corporation | Olfactory receptor of the 7-transmembrane receptor family - OLRCC15 receptor |
WO2001027158A2 (en) * | 1999-10-08 | 2001-04-19 | Digiscents | Olfactory receptor sequences |
Non-Patent Citations (6)
Title |
---|
DATABASE EMBL [Online] AL135841, 21 December 1999 (1999-12-21) N. CORBY: "human DNA sequence from clone RP11-327L3 on chromosome9p13.1-13-3" XP002181513 * |
DATABASE EMBL [Online] AL138834, accession number AL138834, 4 February 2000 (2000-02-04) D. LLOYD: "Human DNA sequence from clone RP11-113A10 on chromosome 9" XP002181514 * |
DATABASE EMBL [Online] MMU133427, accession number AJ133427, 9 September 1999 (1999-09-09) J. STROTMAN ET AL: "Olfactory receptor;or37d gene; pseudogene" XP002181511 cited in the application -& J. STROTMAN ET AL: "Small subfamily of olfactory receptor genes: Structural features, expression pattern and genomic organization" GENE., vol. 236, 1999, pages 281-291, XP004178064 ELSEVIER BIOMEDICAL PRESS. AMSTERDAM., NL ISSN: 0378-1119 * |
DATABASE EMBL [Online] MMU133428, accession number AJ133428, 9 September 1999 (1999-09-09) J. STROTMAN: "Olfactory receptor or37e gene" XP002181512 -& J. STROTMAN ET AL: "Small subfamily of olfactory receptor genes: structural features, expression pattern and genomic organization" GENE, vol. 236, 1999, pages 281-291, XP004178064 * |
ROUQUIER S ET AL: "Distribution of olfactory receptor genes in the human genome" NATURE GENETICS, NEW YORK, NY, US, vol. 18, no. 3, March 1998 (1998-03), pages 243-250, XP002111208 ISSN: 1061-4036 * |
See also references of EP1263952A2 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528599A (en) * | 2000-03-14 | 2003-09-30 | トゥラリック インコーポレイテッド | G protein-coupled receptor |
WO2001077155A2 (en) * | 2000-04-06 | 2001-10-18 | Curagen Corporation | Orfx polynucleotides and polypeptides |
WO2001077155A3 (en) * | 2000-04-06 | 2003-09-25 | Curagen Corp | Orfx polynucleotides and polypeptides |
WO2002050117A2 (en) * | 2000-12-18 | 2002-06-27 | Curagen Corporation | G-proteins coupled receptor proteins and nucleic acids encoding same |
WO2002050117A3 (en) * | 2000-12-18 | 2003-08-14 | Curagen Corp | G-proteins coupled receptor proteins and nucleic acids encoding same |
Also Published As
Publication number | Publication date |
---|---|
CA2401453A1 (en) | 2001-09-07 |
JP2004500098A (en) | 2004-01-08 |
EP1263952A2 (en) | 2002-12-11 |
AU2001241859A1 (en) | 2001-09-12 |
WO2001064879A3 (en) | 2002-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU728102B2 (en) | IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof | |
CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
Wallenius et al. | Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors | |
CA2364567A1 (en) | Human breast and ovarian cancer associated gene sequences and polypeptides | |
JP2005512515A5 (en) | ||
AU2010202764B2 (en) | Single domain TDF-related compounds and analogs thereof | |
JP2003505075A5 (en) | ||
US20080274115A1 (en) | Soluble ErbB3 Methods of Detection and Antibodies | |
WO1998022499A2 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO1998022499A9 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO2001064879A2 (en) | G-proteins coupled receptor related polypeptides | |
WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
JP2005528080A5 (en) | ||
Tanaka et al. | Expression of a dystrophin-like protein on the surface membrane of muscle cells in mdx mice | |
JP2002300891A (en) | New compound | |
JP2005528886A5 (en) | ||
JP2003510029A (en) | EGFH2 gene and gene product | |
JP2005506833A5 (en) | ||
MX2007008559A (en) | Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action. | |
AU2009210387A8 (en) | Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use | |
JP2005526507A5 (en) | ||
WO2004039332A2 (en) | Methods for using osteocalcin | |
CA2481478A1 (en) | Stimulation of nerve cell regeneration | |
AU2013203382A1 (en) | Single domain TDF-related compounds and analogs thereof | |
JP2005504514A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US US US US US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US US US US US US US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401453 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564362 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001913168 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001241859 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001913168 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001913168 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |